Followers | 145 |
Posts | 27566 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Tuesday, August 06, 2013 11:21:15 AM
Gali Weinreb
Compugen shows life sciences companies that invest heavily in science can achieve a breakthrough, even after the capital market has given up on them.
5 August 13 16:43, Gali Weinreb
Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN), founded in the 1990s, was one of the prominent companies in the bio-informatics wave (combining computers and biology) that swept the world. It was believed at the time that cracking the genome and other advances in biology would move the drug discovery process from the laboratory to the computer. But the revolution stalled. Although computer systems improve the drug discovery process, most of the work is still done in the laboratory. Meanwhile, bio-informatics companies were stuck.
Compugen developed a system for automated data mining of biological information from a range of sources. When it was floated on Nasdaq in 2000, its business model was based on the sale of its data mining services to big pharma companies as user fees. Although it signed many cooperation agreements, revenue never exceeded a few million dollars a year.
In 2004, Compugen changed its business model to independently discover and develop drugs on the basis of its computing capabilities. It replaced all its management, board of directors, and a substantial part of its employees (mathematicians replaced biologists). But this did not help either, until the company found the right business model.
In 2010, Compugen decided to focus only on immune checkpoint drugs - molecules that induce the immune system to attack malignant tumors itself. One drug from this group, Yervoy, developed by Bristol Myers Squibb Co. (NYSE: BMY), was a great success, and other pharmaceutical companies rushed after other molecules from this group. Compugen's agreement today with Bayer Healthcare suggests that the bet paid off.
Compugen's story teaches that life sciences companies that invest heavily in time and effort in science over many years can achieve a breakthrough, even after the capital market has given up on them. This assumes that the outstanding science is accompanied by successful management (CEO Dr. Anat Cohen-Dayag) and a party that backs the company financially or can keep capital market enthusiasm alive (chairman Martin Gerstel).
But the lesson of the story is that it is not necessarily worthwhile to accompany a life sciences company all the way. Although Compugen's current market cap is double its IPO value, there were times when it was traded at a 90% discount on its IPO price.
Early investors in companies with such long roads rarely make a profit. When was it worthwhile to invest in Compugen? In 2010, when Cohen-Dayag announced that it was again changing direction, but by then, the market found it difficult to believe.
Published by Globes [online], Israel business news - www.globes-online.com - on August 5, 2013
Recent CGEN News
- Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 • PR Newswire (US) • 05/06/2024 11:00:00 AM
- Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 • PR Newswire (US) • 04/25/2024 11:00:00 AM
- Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 • PR Newswire (US) • 04/10/2024 11:00:00 AM
- Compugen to Participate in Two Upcoming Investor Conferences • PR Newswire (US) • 04/03/2024 11:00:00 AM
- Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy • PR Newswire (US) • 03/11/2024 11:00:00 AM
- Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 • PR Newswire (US) • 03/06/2024 12:00:00 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/05/2024 09:06:21 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 12:00:24 PM
- Compugen Reports Fourth Quarter and Full Year 2023 Results • PR Newswire (US) • 03/05/2024 12:00:00 PM
- U.S. Futures Dip, Crude Oil Fluctuates • IH Market News • 03/05/2024 11:05:54 AM
- Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 • PR Newswire (US) • 02/26/2024 12:00:00 PM
- Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 • PR Newswire (US) • 02/20/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/15/2024 12:00:08 PM
- Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer • PR Newswire (US) • 02/15/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 12:10:06 PM
- Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer • PR Newswire (US) • 01/08/2024 12:05:00 PM
- Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement • PR Newswire (US) • 01/08/2024 12:00:00 PM
- Strong Open For Biotech Following Exclusive Agreement Announcement • AllPennyStocks.com • 12/19/2023 02:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/19/2023 12:12:07 PM
- Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer • PR Newswire (US) • 12/19/2023 12:10:00 PM
- Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology • PR Newswire (US) • 12/19/2023 12:05:00 PM
- Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program • Business Wire • 12/19/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/07/2023 12:00:05 PM
- Compugen Reports Third Quarter 2023 Results • PR Newswire (US) • 11/07/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/06/2023 12:00:07 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM